GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longeveron Inc (NAS:LGVN) » Definitions » Financial Strength

Longeveron (Longeveron) Financial Strength : 3 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Longeveron Financial Strength?

Longeveron has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

Longeveron Inc displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Longeveron's interest coverage with the available data. Longeveron's debt to revenue ratio for the quarter that ended in Dec. 2023 was 8.10. As of today, Longeveron's Altman Z-Score is -14.50.


Competitive Comparison of Longeveron's Financial Strength

For the Biotechnology subindustry, Longeveron's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longeveron's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longeveron's Financial Strength distribution charts can be found below:

* The bar in red indicates where Longeveron's Financial Strength falls into.



Longeveron Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Longeveron's Interest Expense for the months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2023 was $-5.44 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.45 Mil.

Longeveron's Interest Coverage for the quarter that ended in Dec. 2023 is

GuruFocus does not calculate Longeveron's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Longeveron Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Longeveron's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.593 + 1.448) / 0.252
=8.10

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Longeveron has a Z-score of -14.50, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -14.5 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Longeveron  (NAS:LGVN) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Longeveron has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Longeveron Financial Strength Related Terms

Thank you for viewing the detailed overview of Longeveron's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Longeveron (Longeveron) Business Description

Traded in Other Exchanges
N/A
Address
1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136
Longeveron Inc is a clinical-stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of its leased facilities in Miami, Florida. The company has generated revenue from three sources: 1) Grant awards. 2) The Bahamas Registry Trial. 3) Contract development and manufacturing services.
Executives
Cathy Ross director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Khoso Baluch director 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Jeffrey Pfeffer director
Lisa Locklear officer: Chief Financial Officer 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Nataliya Agafonova officer: Chief Medical Officer 1951 NW 7TH AVENUE, MIAMI FL 33136
James Clavijo officer: CFO and Treasurer 1691 MICHIGAN AVE SUITE 435, MIAMI FL 33139
Hashad Mohamed Wa'el Ahmed officer: Chief Executive Officer SUITE 520, 1951 NW 7TH AVE., MIAMI FL 33136
Joshua Hare director, officer: Chief Scientific Officer C/O 470 NAUTILUS STREET, SUITE 300, LA JOLLA CA 92073
Rock Soffer director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Kwan-hong Christopher Min officer: Chief Medical Officer 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Todd C Girolamo director 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Geoff Green officer: CEO 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Paul T Lehr officer: General Counsel, Secretary 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Ursula Ungaro director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Donald M Soffer director, 10 percent owner 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136